Recro Pharma Inc (REPH) was Initiated by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Sep 16, 2016.
Recro Pharma Inc opened for trading at $9.4899 and hit $9.5879 on the upside on Wednesday, eventually ending the session at $9.4, with a gain of 0.64% or 0.06 points. The heightened volatility saw the trading volume jump to 7,566 shares. Company has a market cap of $93 M.
In a different news, on Jun 2, 2016, Fred Graff (Chief Commercial Officer) purchased 8,000 shares at $8.46 per share price. According to the SEC, on May 31, 2016, Stewart Mccallum (Chief Medical Officer) purchased 1,250 shares at $8.32 per share price. On May 25, 2016, Randall Mack (Senior VP, Development) purchased 2,000 shares at $6.30 per share price, according to the Form-4 filing with the securities and exchange commission.
Recro Pharma Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN Dex-SL and Fadolmidine (Fado). Dex-IN is a product candidate under development for the treatment of post-operative pain and for the treatment of cancer breakthrough pain. Dex-SL is a product candidate for the treatment of chronic pain. Fado is a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies) especially of the lower extremities which can occur in diabetic patients.